Germany hands back royal-era artefacts to Ethiopia
Germany has returned 12 royal-era cultural artefacts to Ethiopia in a ceremony in Addis Ababa, marking a formal step in ongoing cultural cooperation b...
German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said.
CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at €1.04 billion ($1.2 billion), while BioNTech shares were down 2%.
The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke.
"With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," the company said.
CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK.
It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic.
GERMAN BIOTECH CHAMPION
The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress.
CureVac shares were worth as much as €120 in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at €4.65.
BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.
Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said.
If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.
BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac.
The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer.
Thousands of users in the United States, some parts of Europe and South America on the X (formerly twitter) platform have reported being unable to access the site due to Cloudflare outage.
Emirates Airline is confident in Boeing’s plans for a larger 777X and has ruled out ordering Airbus’s A350-1000 at the Dubai Airshow.
Punjab’s modern political story begins in 1947. The end of British rule divided the region between India and Pakistan, leaving Sikh communities with a split homeland and unresolved questions about cultural and administrative protections.
Iran's air force, heavily reliant on aging F-14A Tomcat jets, faces a growing technological gap as its neighbors rapidly modernize their air forces with advanced fighter jets and air defense systems.
China's Foreign Minister Wang Yi on Tuesday talked up "high-level exchanges" in a call with Japanese counterpart Toshimitsu Motegi, hinting at a potential meeting between Chinese President Xi Jinping and Japan's new premier, Sanae Takaichi.
A recent study shows that women face a higher risk of job loss due to artificial intelligence (AI) and are 20% less likely than men to use generative AI tools, reducing their chances of working in AI-reliant roles.
There are 29 confirmed cases of the mpox virus in Portugal according to local authorities, which reported in the past three months that there were 10 people in August, three in September, and 16 others in October.
A prostate cancer blood test has been shown to reduce the risk of dying from the disease by 13% over two decades, researchers say.
Serious cases of a disorder of the large intestine are surging among Americans younger than 50, researchers say.
Russian President Vladimir Putin asked North Korean Foreign Minister Choe Son Hui during talks in the Kremlin on Monday to tell her country's leader Kim Jong Un that everything was "going to plan" in bilateral relations.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment